Metabolic Reprogramming to Improve Immunotherapy (R21)
Metabolic Reprogramming to Improve Immunotherapy (R21) The overall objective of this funding chance announcement (FOA) is to encourage R21 exploratory/developmental grant applications to (a) produce a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) figure out how the metabolic landscape of the growth microenvironment impacts immune effector functions, […]
Metabolic Reprogramming to Improve Immunotherapy (R21) Read More »